$JNJ · JOHNSON & JOHNSON
Johnson & Johnson filed an 8-K with Q3 2026 supplementary sales data and condensed financials. Worldwide sales rose 5.9% to $25.4B (operational +6.0%). GAAP net earnings collapsed 95.9% to $210M ($0.09/share) from $5.15B ($2.12) due to a $5.52B litigation charge and a $339M IPR&D impairment. Adjusted EPS of $2.59 missed the year-ago $2.80 by 7.5%. Innovative Medicine grew 7.7% led by DARZALEX (+15.4%) and TREMFYA (+68.3%), while STELARA fell 54.4% on biosimilar competition. MedTech rose 2.5% to $8.6B.
- GAAP net earnings collapsed to $210M from $5.15B YoY, driven by a $5.52B litigation-related pre-tax charge in Q3 2026.
- Adjusted EPS of $2.59 fell 7.5% vs. $2.80 in Q3 2025; nine-month adjusted EPS of $8.19 vs. $8.33.
- Worldwide Q3 sales rose 5.9% to $25.4B; Innovative Medicine grew 7.7% to $16.8B, MedTech up 2.5% to $8.6B.
- STELARA revenue cratered 54.4% to $716M on biosimilar competition; OPSUMIT/OPSYNVI fell 35.7% to $372M.
- R&D expense surged 26.7% to $4.65B; Other (income)/expense swung to a $5.78B charge from a $478M gain last year.
Extended-hours trading shows JNJ at $258.48, down 1.99% from the regular close of $263.73, indicating the market is reacting negatively to the massive GAAP earnings miss and litigation charge despite in-line adjusted results.
A $5.5B litigation charge vaporized nearly all of J&J's quarterly GAAP profit, and even adjusted earnings declined 7.5% — a rare double miss for the $635B healthcare giant.
J&J's results mirror the broader pharma challenge of defending legacy blockbusters (STELARA -54%, REMICADE -17%) while leaning on oncology growth drivers like DARZALEX (+15.4%) and CARVYKTI (+35.5%). The $5.5B litigation charge is outsized even by industry standards.
The $5.52B litigation charge signals ongoing talc/opioid liability exposure. STELARA and OPSUMIT/OPSYNVI face accelerating biosimilar/generic erosion. R&D spend jumped 26.7% with no guarantee of pipeline returns.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.